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leads to a novel class of potent tri-vector
cyclophilin inhibitors†
Alessio De Simone,a Charis Georgiou,a Harris Ioannidis, a Arun A. Gupta,a
Jordi Jua´rez-Jime´nez, a Dahlia Doughty-Shenton,b Elizabeth A. Blackburn,c
Martin A. Wear,c Jonathan P. Richards,a Paul N. Barlow,a Neil Carragher,d
Malcolm D. Walkinshaw,e Alison N. Hulme a and Julien Michel *a
Cyclophilins (Cyps) are amajor family of drug targets that are challenging to prosecute with small molecules
because the shallow nature and high degree of conservation of the active site across human isoforms offers
limited opportunities for potent and selective inhibition. Herein a computational approach based on
molecular dynamics simulations and free energy calculations was combined with biophysical assays and
X-ray crystallography to explore a flip in the binding mode of a reported urea-based Cyp inhibitor. This
approach enabled access to a distal pocket that is poorly conserved among key Cyp isoforms, and led to
the discovery of a new family of sub-micromolar cell-active inhibitors that offer unprecedented
opportunities for the development of next-generation drug therapies based on Cyp inhibition. The
computational approach is applicable to a broad range of organic functional groups and could prove
widely enabling in molecular design.Introduction
In the absence of innovative treatments, the societal burden of
neurodegenerative disorders is projected to grow substantially
over the next few decades worldwide. A growing body of
evidence points to the central role of the opening of the mito-
chondrial permeability transition pore (mPTP) in neurodegen-
erative cell death.1 The enzyme cyclophilin D (CypD) is an
essential regulator of the mPTP opening, and blockage of CypD
function is neuroprotective in models of Alzheimer's and Par-
kinson's diseases.2–4 Besides neurodegenerative disorders,ilding, King's Buildings, David Brewster
-mail: mail@julienmichel.net
versity of Edinburgh, Queen's Medical
urgh, Scotland, EH16 4TJ, UK
(EPPF), University of Edinburgh, Level 3
ax Born Crescent, Edinburgh, Scotland,
niversity of Edinburgh, MRC Institute of
Road South, Edinburgh, Scotland, EH4
uilding, Max Born Crescent, Edinburgh,
ESI) available: Chemical synthesis and
mputational, biochemical, biophysical
structures of 2, 4, 5, 7, 8, 9, 10, 15 in
in the Protein Data Bank (PDB codes
6GJL, 6GJN respectively). See DOI:CypD inhibition is protective in animal models of acute kidney
injury, a condition that accounts for a h of emergency
hospitalizations in the USA.5 Other related cyclophilin isoforms
CypA and CypB are overexpressed in malignant cancers,6 and
CypA inhibition has potent antiviral and anti-inammatory
effects.7 Cyp inhibition may also protect the liver from brosis
subsequent to non-alcoholic steatohepatitis (NASH), a common
indication for liver transplantation aer chronic hepatitis C.8
The majority of existing Cyp inhibitors are derived from the
natural products cyclosporin A (CsA) and sanglifehrin A.9 These
scaffolds achieve potent inhibition but are complex to synthe-
size, lack sub-type selectivity, show undesirable side-effects, and
have poor CNS activity. Extensive efforts have been pursued to
simplify these scaffolds into more synthetically tractable vari-
ants.10–13 There is also considerable interest in developing small
molecule Cyp inhibitors that may be more easily optimized for
use as therapeutics.14–20 However, there are few reports of well
characterized small molecules that bind strongly to Cyps.21,22
Current small molecule design strategies typically feature linear
(thio)ureas15,23 or amides24 as scaffolds. Compound 1 provides
an example that exploits interactions with residues in the highly
conserved Pro and Abu pockets (Fig. 1A). Fig. 1A also highlights
a less conserved distal three o'clock pocket that is thought to
offer prospects for potency and selectivity improvements,25 but
to date it is unclear how this pocket can be engaged using
current scaffolds.
Herein we report a multidisciplinary approach to redesign-
ing linear Cyp inhibitor scaffolds into the rst class of tri-vectorThis journal is © The Royal Society of Chemistry 2019
Fig. 1 (A) Surface representation of the PPIAse domain coloured by
residue conservation across human Cyp A–D isoforms. The location of
Abu, Pro and 3 o'clock pockets are highlighted and compound 1 is
shown in coloured sticks. (B) Distribution of distances between urea
nitrogen atoms in 1 and Asn102 backbone oxygen observed in MD
simulations. (C) Interactions of 1 with CypA residues in a canonical
type-I binding mode. (D) Hypothesized type-II binding mode for
alkylated urea variants of 1.
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View Article Onlineinhibitors that simultaneously target the Pro, Abu and three
o'clock pockets.Scheme 1 (a) NaBH4, EtOH, RT, 24 hours, yields: 93–95%; (b) K2CO3,
MeCN, 70 C, 6 hours, yields: 95–99%; (c) ethyl isocyanatoacetate,
DCM, RT, overnight, yields: 81–99%; (d) Fe, CaCl2, EtOH/H2O, 90 C, 4
hours, yields: 17–98%. (e) LiOH$H2O, THF/MeOH/H2O, RT, 2 hours,
then 2-(2-bromophenyl)-pyrrolidine, HATU, DIPEA, DMF, RT, over-
night, yields: 9–46% over two steps.Results and discussion
Molecular dynamics simulations suggest a new ligand
optimisation strategy
The protein X-ray structure of 1 in complex with CypA suggests
that both urea nitrogen atoms are hydrogen-bonded to the
backbone oxygen of Asn102.21 However, molecular dynamics
(MD) simulations revealed that the nitrogen atom distal to the
ester moiety in 1 is only weakly interacting with Asn102 and
readily moves away from this residue (Fig. 1B, C and S1†),
suggesting that alkylation of that nitrogen to introduce a new
vector in the scaffold could be tolerated. Ab initio calculations
on model ureas suggest a modest energetic preference for the
Z,Z urea conformer.26 This led to the hypothesis that a suitablyThis journal is © The Royal Society of Chemistry 2019chosen R group could stabilize an alkylated urea in an E,Z
conformer able to adopt a novel type-II binding mode that
would enable access to the 3 o'clock pocket (Fig. 1D).
A general synthetic route to tri-vector cyclophilin ligands
The tri-vector design hypothesis was pursued by synthesis of
a series of alkylated urea ester ligands. The majority of the
compounds were prepared according to Scheme 1 (steps a–d,
see ESI† for details). Substituted amino derivatives were
typically prepared from 4-nitrophenyl derivatives by
reductive amination,27 or nucleophilic substitution.28 The
urea moiety was prepared by condensation of the resulting
amines with ethyl isocyanatoacetate,15 and the desired
products were obtained by subsequent reduction of the nitro
group.29
A free-energy perturbation (FEP) protocol guides the selection
of substituents
MD simulations cannot readily sample the desired type-I to
type-II binding mode ip because rotational barriers of ca.
15 kcal mol1 separate Z,Z and E,Z conformers.30 Free Energy
Perturbation (FEP) calculation methods have shown potential
for optimization of ligand potency and selectivity.31–38 Here the
selection of potential R groups was guided by a novel FEP
protocol designed to compute the energetics of this binding
mode ip (Fig. 2A). The setup, execution and analysis of the FEP
calculations were carried out with the soware FESetup,39
SOMD,40–42 and freenrgworkows.43 The selection of R groups
for computational and experimental evaluation was driven by
the following considerations: lack of obvious steric or electro-
static mismatches, polar or non-polar interactions with 3
o'clock pocket residues, ease of synthesis, diversity of structure–
activity relationships, and validation of FEP-calculated
energetics.Chem. Sci., 2019, 10, 542–547 | 543
Fig. 2 (A) FEP-calculated binding energetics. The figures are relative to 1 in a type-I bindingmode and were obtained from automated analysis of
FEP maps (Fig. S2†). A partial map depicted below the table illustrates how molecule Int04 is used to connect other compounds in a type-I or II
bindingmode. (B) ITC-derived dissociation constants and observed bindingmode in X-ray crystallography derived CypA structures. Uncertainties
on Kd values from fit to a one-site binding model. Partial occupancies are given for compounds refined in multiple binding modes. n.b.: no
binding observed at the maximum concentration tested. n.d.: not determined. (C) X-ray crystal structure of CypA: 2 depicting a type-I binding
mode. (D) X-ray crystal structure of CypA: 9 depicting a type-II binding mode. Fo  Fc electron density omit maps are shown as a green mesh at
2.5s contour (see ESI† for details).
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View Article OnlineCompound 1 was predicted to favour a type-I binding mode
by ca. 1 kcal mol1, in line with the preferences observed in
X-ray structures (Fig. 2A).21 Non-polar substitutions (2, 3, 4, 5, 7)
were predicted to worsen free energies of binding relative to 1
and maintain preference for a type-I binding mode. By contrast
nitrogen-rich 5-membered rings (8, 9, 10) were predicted to
show a similar or slight preference for type-II binding mode.
Ligand binding to CypA was characterized by isothermal
titration calorimetry (ITC) measurements (Fig. 2B). Substitutions
with small linear alkyl groups (2, 4) were tolerated but weakened
binding, whereas branched alkyls (3) were inactive, in line with
the FEP calculations. Alkyne, cyano and cyclopropyl derivatives
(5, 6, 7) were computed to bind with potencies comparable to
linear alkyl groups, but turned out to be very weak binders in the
ITC assay. Nitrogen rich ve-membered rings (8, 9, 10) showed
more favourable binding constants, in line with the FEP calcula-
tions. Piperidines 11 and 12 had not been evaluated by FEP
calculations and turned out to be inactive.
Evidence of binding mode preferences was sought by soak-
ing CypA crystals with compounds 2–12. Seven X-ray structures
of CypA complexes were determined. Compounds 2, 4, 7 were544 | Chem. Sci., 2019, 10, 542–547found to adopt a type-I binding mode in line with the FEP
calculations (Fig. 2C and ESI†). Compound 5 was observed to
adopt dual occupancy, whereas the FEP calculations anticipated
a type-I binding mode. Compound 8 was observed to adopt dual
occupancy, whereas 9 and 10 were only observed in a type-II
binding mode in the X-ray rened structures. The FEP calcula-
tions suggest both binding modes are feasible for these three
compounds. In 8–10 the type-II binding mode is stabilized by
hydrogen-bonding interactions between nitrogen atoms in the
ve-membered rings and His54. This binding mode ip from
type-I to type-II is accompanied by a slight rearrangement in the
orientation of the urea carbonyl to maintain optimal placement
of the aniline ring in the Abu pocket. Strikingly the 5-membered
ring methyl groups in 8 and 9 point into the 3 o'clock pocket of
CypA and provide a clear vector for further derivatization
(Fig. 2D).
The tri-vector design generalises to other ligand families and
Cyp isoforms
With the binding mode ip hypothesis validated for the urea
ester series in CypA, attention turned to transferability of theThis journal is © The Royal Society of Chemistry 2019
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View Article Onlinestrategy to other ligand families and Cyp isoforms. FEP calcu-
lations suggested that a type-II binding mode preference was
maintained for nitrogen-rich heterocycles in the context of
a urea arylpyrrolidine scaffold for both CypA and CypD isoforms
(Fig. S3–S5†).21 Thus alkylated variants 13–16 were prepared
from 4-nitrophenyl ester intermediates (Scheme 1, steps e
and d). Compounds 13–15 feature similar R groups to 5, 8 and
9, whereas 16 was prepared to assess viability of further
extension into the three o'clock pocket via appendage of an
ester group to a triazole. The X-ray crystallography derived
structure of 15 in complex with CypA conrmed that the type-II
binding mode has been maintained (Fig. 3A). Thus 13–16 were
assayed by surface plasmon resonance (SPR) against CypA,
CypB and CypD isoforms. The compounds bind to all three
isoforms with Kd values in the low mM to mid nM range
(Fig. 3B). Compound 15 binds particularly well to CypD, with
a potency (ca. 70 nM) approaching that of CsA (ca. 20 nM). For
comparison the unsubstituted (R ¼ H) urea has been reported
to inhibit CypD with an IC50 of 1.1  0.2 mM.15 Although 13–15
only access the entrance of the three o'clock pocket, the SPR
assay suggests this is sufficient to endow a degree of isoform
selectivity. Compound 16 binds slightly worse to CypA and
CypB but modestly better to CypD with respect to 14. Thus
further lead optimization efforts to tune desired selectivity
proles appear auspicious.Fig. 3 (A) X-ray crystal structure of CypA in complex with 15. (B) SPR-
derived dissociation constants for alkylated urea arylpyrrolidine
ligands. Values are the mean  1s from three repeat experiments.
* ITC-derived Kd value (see ESI† for details).
This journal is © The Royal Society of Chemistry 2019Tri-vector ligands show improved efficacy and decreased
toxicity over cyclosporine in cell assays
Additional evidence for the potential of this tri-vector design
was sought by evaluating 13–15 in cellular assays. CypA has
previously been shown to be necessary for the prolactin-
induced activation of Janus-activated kinase 2 in human
breast cancer cells, with CsA treatment causing inhibition of
growth of the triple negative MDA-MB-231 breast-cancer cell
line.44 Compounds 13 and 15 showed evidence of dose-
dependent growth inhibition at low micromolar concentra-
tion resulting in GI50 values similar (13) or two-fold better (15)
than those measured for CsA. By contrast 14 was inactive
(Fig. 4A and B). Thus alkylation of the urea moiety does not
appear to prevent cell penetration. Negligible cell death was
observed for compounds 13 and 15 suggesting low toxicity in
comparison with CsA. This indicates that in MDA-MB-
231_NLG cells growth inhibition by compounds 13 and 15 is
due to reduced proliferation, whereas growth inhibition by
CsA is also a consequence of cell death (Fig. 4C). Additionally
13–15 showed no growth inhibition or induction of cell death
in the non-tumorigenic broblast IMR-90 cell line. ByFig. 4 (A) Growth inhibition for MDA-MB-231_NLG cells and mean
GI50 with 95% CI [lower limit, upper limit]. (B) MDA-MB-231_NLG cells
after 120 hours treatment; red nuclei indicate dead cells. Area shown is
0.64 mm2, scale bar is 200 mm. (C) % dead MDA-MB-231_NLG cells.
(D) Fold increase of IMR-90 cell confluence (line graphs) and number
of dead IMR-90 cells (bar graphs). Values in panels A, C, D represent
mean  SEM of three independent experiments each performed in
triplicate with 120 hours of treatment.
Chem. Sci., 2019, 10, 542–547 | 545
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View Article Onlinecontrast CsA induced signicant growth inhibition and cell
death (Fig. 4D).
Thus, further evaluation of the present tri-vector Cyp inhib-
itors in a range of in vitro and in vivo disease models implicating
Cyps seems to be warranted, particularly in instances where CsA
toxicity and off-target effects have been a cause for concern.
Alternatives to the aniline moiety in 15 to alleviate toxicity
concerns have been suggested elsewhere.21,45 Immunosuppres-
sion via inhibition of calcineurin phosphatase activity is
a well-known feature of CsA. The tri-vector Cyp inhibitors are
unlikely to possess this capability given that the parent urea-
arylpyrrolidine compounds they are derived from lack calci-
neurin inhibition properties.21Conclusions
In summary, this work has validated a strategy for the redesign
of existing cyclophilin inhibitors into a novel class of inhibitors
that can simultaneously target three pockets on the surfaces of
cyclophilins. This breakthrough has led to signicantly more
potent cyclophilin inhibitors and also opens up new horizons to
optimise isoform-selectivity. Nanomolar acylurea-based cyclo-
philin inhibitors have been reported previously,46 but subse-
quent work was unable to reproduce these ndings or to detect
evidence of binding to cyclophilins for these molecules.21
Members of the tri-vector class of cyclophilin inhibitors (13, 15)
show improved efficacy and reduced toxicity in cell assays over
the drug cyclosporine A. They are thus already attractive leads
for new drug therapies based on Cyp inhibition. To our
knowledge this is the rst example of the validation of an FEP
methodology to computationally design a large scale binding
mode ip in a protein–ligand complex. The approach is readily
applicable to a broad range of commonly encountered organic
functional groups that exhibit E/Z conformational equilibria.
We anticipate that this methodology may be of widespread
utility to facilitate ligand optimisations in structure-based drug
design efforts.Conflicts of interest
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